Compare Illumina, Inc. (ILMN) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs JPMorgan Equity Premium Income ETF — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while JPMorgan Equity Premium Income ETF trades at $56.77 (market cap $45.55B). The key difference: Illumina, Inc. and JPMorgan Equity Premium Income ETF are close in size by market cap, and Illumina, Inc. is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and JPMorgan Equity Premium Income ETF for 57 Days on average.
| ILMN | JEPI | |
|---|---|---|
Market Cap | $39.95B | $45.55B |
Volume | 3,169,503 | 3,820,809 |
Sector | Health | Income / Options Overlay |
52-Week High | $293.69 | $59.88 |
52-Week Low | $91.00 | $55.29 |
Typical Hold Time | 83 Days | 57 Days |
Enterprise Value | $41.31B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $264.40, down 1.25% on the day but remains near its 52-week high of $278.99, reflecting strong momentum with a 94.9% YTD gain. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Fundamentals show a significant turnaround, with net income reaching $850 million in 2025 after prior losses, supported by robust gross margins of 66.38%. Technical indicators are bullish overall, with key support at $257 and resistance at $268.
The outlook for ILMN is positive, driven by earnings momentum, inclusion in the S&P 500, and strategic AI initiatives in genomics. However, risks include high valuation multiples, such as a P/E of 49.36, and potential margin pressure from cost volatility. Analyst consensus is bullish with a 54% buy rating, though the consensus price target of $241 suggests limited near-term upside from current levels.
JEPI trades at $56.67, up 0.39% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF shows consistent dividend distributions with recent payments of $0.37 in August and July 2026. Media coverage focuses on income strategies and tax implications, with Seeking Alpha highlighting JEPI's role as a hedge against tech-led market declines.
The outlook remains income-focused with steady monthly distributions, though covered-call strategies may limit upside during rallies. Key risks include interest rate sensitivity and tax inefficiencies, while institutional interest continues with Envestnet increasing its stake by 20.9% in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →
